Revenue
No reported data
Olema Pharmaceuticals, Inc. (OLMA)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2024
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Research & development | $157.7M | $124.5M | $86.1M | $82.3M | $51.1M | $13.7M | $3.9M |
| Operating expenses | $178.7M | $142.3M | $105.0M | $107.0M | $71.5M | $21.5M | $4.3M |
| Operating income | −$178.7M | −$142.3M | −$105.0M | −$107.0M | −$71.5M | −$21.5M | −$4.3M |
| EBITDAderived | −$178.2M | −$141.9M | −$104.6M | −$106.6M | −$71.3M | −$21.5M | −$4.3M |
| Net income | −$162.5M | −$129.5M | −$96.7M | −$104.8M | −$71.1M | −$22.1M | −$4.3M |
| Basic EPSper diluted share | -$1.87 | -$2.20 | -$2.14 | -$2.62 | -$1.80 | -$3.42 | -$1.66 |
| Diluted EPSper diluted share | -$1.87 | -$2.20 | -$2.14 | -$2.62 | -$1.80 | -$3.42 | -$1.66 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 4, 2026Form 4 | Mitchell ShawnteCHIEF LEGAL OFFICER | SellComon Stock | 233 | $24.69 | $5.8K | 0 |
| Mar 4, 2026Form 4 | Mitchell ShawnteCHIEF LEGAL OFFICER | SellCommon Stock | 24.8K | $24.25 | $600.6K | 233 |
| Mar 3, 2026Form 4 | Mitchell ShawnteCHIEF LEGAL OFFICER | SellCommon Stock | 15.0K | $23.01 | $345.1K | 0 |
| Jan 20, 2026Form 4 | Harmon CyrusDirector | SellCommon Stock | 10.0K | $26.88 | $268.8K | 727.8K |
| Jan 15, 2026Form 4 | Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. | SellCommon Stock | 100.0K | $28.73 | $2.87M | 139.7K |